# Evaluation of the Efficacy and Safety of MV140

> **NCT02543827** · PHASE3 · COMPLETED · sponsor: **Inmunotek S.L.** · enrollment: 240 (actual)

## Conditions studied

- Urinary Tract Infection Bacterial

## Interventions

- **BIOLOGICAL:** MV140
- **BIOLOGICAL:** Placebo

## Key facts

- **NCT ID:** NCT02543827
- **Lead sponsor:** Inmunotek S.L.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-11
- **Primary completion:** 2020-11-04
- **Final completion:** 2020-12
- **Target enrollment:** 240 (ACTUAL)
- **Last updated:** 2021-02-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02543827

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02543827, "Evaluation of the Efficacy and Safety of MV140". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02543827. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*